P0898 - Inflammatory Bowel Disease Among COVID-19 Hospitalizations: An Analysis of the National Inpatient Sample

Anwar Uddin, MD¹, Prashil Dave, MD², Peter Lymberopoulos, MD¹, Justin Chung, MD³, Aboud Kaliounji, MD², Madia Ahad, MD¹, Rafat Uddin, BA¹, Rahat Uddin, MS¹, Afgal Ahad, MD^1
1SUNY Downstate Medical Center, Brooklyn, NY; ²State University of New York Downstate, Brooklyn, NY; ³SUNY Downstate Health Sciences University, Brooklyn, NY

Introduction: Many studies have indicated that Covid-19 infection is associated with higher risk of mortality in inflammatory bowel disease (IBD) due to potentially overlapping pathophysiology. We conducted a nationwide study to examine the prevalence and inpatient outcomes of IBD, ulcerative colitis (UC) and Crohn’s disease (CD) in covid-19 patients using the nationwide database.

Methods: We used the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) to identify adult patients admitted with covid-19 infection in 2020 using ICD-10-CM codes (U.071, U.00, U.49, U.50, U.85, J.1282, and B.342). We used ICD-10-CM codes to identify patients with IBD, CD and UC. Main outcomes were in-hospital mortality, length of stay (LOS), and hospital costs. We evaluate the association between IBD, CD and UC and outcomes using survey based multivariate logistic regression models for in-hospital mortality, Poisson regression for LOS, and generalized linear model with gamma distribution and log link for hospitalization cost. Models were adjusted for age, sex, race and ethnicity, primary payer, Charlson comorbidity index, hospital bed size, hospital region and hospital teaching status.

Results: We identified a total of 1,540,935 covid-19 hospitalizations in 2020 in the United States and 9,270 (0.60%) of them were associated with IBD (4,855, 0.32% for CD; and 4,430, 0.29% for UC). Rate of IBD among covid-19 showed increasing trends across the admission months (0.52% in March to 0.64% in December, p = 0.005) which was majorly contributed by UC (0.23% in March to 0.29% in December, P < 0.001 for UC vs 0.29% in March to 0.35% in December, P = 0.6). In‐patient mortality was not significantly different in IBD patients with covid-19 compared to non-IBD patients with covid-19 (12% vs 13%, adjusted OR: 0.98, 95%CI: 0.84-1.15, P = 0.8, Table 1). Also, length of stay (8.1 ± 0.20 vs 8.1 ± 0.04 days, P = 0.061) and cost of hospitalization ($21,001 ± 746 vs $21,807 ± 231, P = 0.2, Table 1) were not significantly different IBD patients with covid-19 compared to non-IBD patients with covid-19. While UC patients with covid-19 has increased length of stay and increased cost of hospitalization (Table 1).

Discussion: About 0.6% of covid-19 patients has IBD diagnosis and covid-19 patients with IBD is not associated with in‐hospital mortality, LOS and cost of hospitalization but higher increased length of stay and increased cost of hospitalization was found for covid-19 patients with UC.


Disclosures:


Anwar Uddin, MD¹, Prashil Dave, MD², Peter Lymberopoulos, MD¹, Justin Chung, MD³, Aboud Kaliounji, MD², Madia Ahad, MD¹, Rafat Uddin, BA¹, Rahat Uddin, MS¹, Afgal Ahad, MD¹. P0898 - Inflammatory Bowel Disease Among COVID-19 Hospitalizations: An Analysis of the National Inpatient Sample, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.